Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Dashpagam, Otgonbayar

Loading...
Thumbnail Image
Товч нэр
Dashpagam, Otgonbayar
Бүтэн нэр
Dashpagam Otgonbayar
Латин нэр
Dashpagam Otgonbayar
Албан тушаал
Судлаач
Харьяалал

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Impact of Booster Vaccination on Infection and Hospitalization Rates during the Mass Vaccination in Mongolia
    (Mongolian National University of Medical Sciences, 2025-09-30)
    Dashpagam, Otgonbayar
    ;
    Batmunkh, Burenjargal
    ;
    Gunchin, Batbaatar
    ;
    Lkhagvasuren, Khorolsuren
    ;
    Davaalkham, Dambadarjaa
    Objective: Our study aims to evaluate the effectiveness of booster vaccination in preventing new COVID-19 infections and related hospitalizations among groups that received the primary vaccination series. Methods: Booster vaccination started on August 31, 2021, at recruitment in May 2022. By May 2022, 64% of the Mongolian population had received two primary doses of a COVID-19 vaccine, and 31% had received a booster dose. We followed 1,251 participants (459 males and 792 females, with a mean age of 41.5 ± 14.5 years [18–93], and a median age of 39.0 years) over six months, from the start of booster immunization on September 1, 2021, to February 28, 2022. We compared infection and hospitalization rates among vaccinated groups using logistic regression and calculated vaccine effectiveness (VE) for booster recipients with the formula: VE = 1 – (vaccinated rate/unvaccinated rate) × 100. Results: All participants received two doses of one of four vaccines used in the nationwide campaign. During the study period, we identified 449 new infection cases, accounting for 35.9% of all participants, and 150 subsequent hospitalizations, or 12.0% of the total. Participants who did not receive a booster demonstrated significantly higher infection rates compared to those who did. Booster vaccination provided notably better protection against new infections among frontline workers and reduced hospitalizations in high-risk groups. No significant differences were found in VE when comparing participants based on seroconversion after initial vaccination or the type of booster vaccine used.Conclusion: Therefore, we concluded that COVID-19 booster vaccinations effectively enhanced protection against new SARS-CoV-2 infections among frontline healthcare workers, government employees, and individuals at higher risk for severe disease, thereby reducing their risk of hospitalization.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    The potential cost-effectiveness of HPV vaccination among girls in Mongolia
    (2022-08)
    Luvsan, Munkh-Erdene
    ;
    Vodicka, Elisabeth
    ;
    Jugder, Uranbolor
    ;
    Tudev, Undarmaa
    ;
    Clark, Andy
    INTRODUCTION: Cervical cancer is a leading cause of cancer among women in Mongolia with an age-standardized incidence rate of 23.5 per 100,000. HPV vaccination has not been introduced nationally and Gavi co-financing support is not available in Mongolia. Extended Gavi pricing for HPV vaccine may be available from vaccine manufacturers for a number of years. To inform introduction decision-making, we evaluated the potential cost-effectiveness of HPV vaccination among girls and young women in Mongolia. METHODS: We used UNIVAC (version 1.4), a static decision model, to evaluate the health and economic outcomes of single-cohort vaccination among females from the government perspective compared to no vaccination. We modeled vaccine introduction over 10 birth cohorts starting in 2022 comparing quadrivalent or bivalent vaccine selection and vaccine pricing variations. We used locally-specific data for cancer incidence, mortality, treatment and costs. Model outcomes included cancer cases, hospitalizations, deaths, disability-adjusted life years (DALY), and costs presented in 2018 USD. Incremental costs and health outcomes were discounted at 3% and aggregated into an Incremental Cost-Effectiveness Ratio (ICER). RESULTS: The base-case scenario of HPV vaccination among 9 year-old girls was projected to avert 5,692 cervical cancer cases, 3,240 deaths, and 11,886 DALYs and incur $2.4-3.1M more costs compared to no vaccination. At prices of ($4.50-$4.60/dose), we estimated an ICER of $166-$265/DALY averted among 9-year-olds. When price per dose was increased to reported mean vaccine purchase price for non-Gavi LMICs ($14.17/dose), the ICER ranged from $556-820/DALY averted. CONCLUSION: HPV vaccination among girls is highly likely to be a cost-effective investment in Mongolia compared to no vaccination with projected ICERs less than 20% of the 2018 GDP per capita of $3,735.
    Scopus© Citations 5